Loading organizations...
§ Private Profile · 100 Technology Center Drive, Suite 300, Stoughton, MA, USA
Specialty pharmaceutical company developing and commercializing medications for pain management and ADHD in the US.
Collegium Pharmaceutical is a publicly traded specialty pharmaceutical company based in Stoughton, Massachusetts, that develops and commercializes differentiated medications for serious medical conditions. Operating primarily in the United States through direct sales, the enterprise focuses on responsible pain management and neuropsychiatry treatments for healthcare professionals and patients. The organization's core portfolio features prescription pain medications including Xtampza ER, Belbuca, and Nucynta, which target individuals suffering from moderate to severe pain. On September 3, 2024, the company expanded its therapeutic focus by acquiring Ironshore and its flagship product Jornay PM, an ADHD treatment designed for patients aged six years and older. Traded on the NASDAQ exchange under the ticker COLL, the business is currently led by Chief Executive Officer Vikram Karnani alongside Chairman Gino Santini. Collegium Pharmaceutical was originally founded in April 2002 by Michael Heffernan.
Collegium Pharmaceutical has raised $73.0M across 2 funding rounds.
Collegium Pharmaceutical has raised $73.0M in total across 2 funding rounds.
Collegium Pharmaceutical has raised $73.0M in total across 2 funding rounds.
Collegium Pharmaceutical's investors include Eran Nadav, Adage Capital Management, Aperture Venture Partners, Boston Millennia Partners, EcoR1 Capital, Eventide Asset Management, Frazier Healthcare Partners, Longitude Capital, RA Capital Management, Rock Springs Capital, Skyline Ventures, David Hirsch.
Collegium Pharmaceutical has raised $73.0M across 2 funding rounds. Most recently, it raised $50.0M Other Equity in March 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 10, 2015 | $50M Venture Round | Eran Nadav | Adage Capital Management, Aperture Venture Partners, Boston Millennia Partners, EcoR1 Capital, Eventide Asset Management, Frazier Healthcare Partners, Longitude Capital, RA Capital Management, Rock Springs Capital, Skyline Ventures | Announced |
| Feb 1, 2012 | $23M Series B | David Hirsch, Stephen J. Hoffman | Frazier Healthcare Partners, PAT Fortune | Announced |
Collegium Pharmaceutical is a biopharmaceutical company, not a technology company in the traditional tech sense, focused on developing and commercializing differentiated medications for serious medical conditions using its proprietary DETERx platform technology for abuse-deterrent products.[1][2][3] It serves patients with serious medical conditions and healthcare professionals, addressing unmet needs in pain management and related therapies through a portfolio of innovative, science-led medicines that prioritize patient outcomes and community well-being.[1][2] The company demonstrates growth momentum as a leading, diversified player in the biopharma space, emphasizing responsible corporate citizenship alongside commercial expansion.[1][2]
Collegium Pharmaceutical emerged as a specialty pharmaceutical company centered on its DETERx platform technology, which enables the development of abuse-deterrent formulations to mitigate risks associated with opioid and pain medications.[3] While specific founding details like exact year or individual founders are not detailed in available sources, the company's evolution reflects a commitment to building a diversified biopharmaceutical portfolio, evolving from a focus on abuse-deterrent innovations to a broader mission of supporting patients and communities with serious conditions.[1][2] Pivotal moments include establishing core values that guide its biopharma business, CSR efforts, and customer relationships, solidifying its position in the sector.[2]
Collegium stands out in the biopharmaceutical landscape through these key strengths:
Collegium rides the trend of advanced drug delivery technologies in biopharma, particularly abuse-deterrent formulations amid the ongoing opioid crisis and demands for safer pain management solutions.[3] Timing is critical as regulatory pressures and public health initiatives favor innovations like DETERx, which address misuse risks while meeting therapeutic needs—market forces including rising chronic disease prevalence and payer preferences for responsible therapies work strongly in its favor.[1][3] By influencing the ecosystem through its portfolio and community focus, Collegium contributes to healthier outcomes, shaping standards for ethical biopharma innovation beyond pure tech startups.[1][2]
Collegium is poised to expand its diversified portfolio with further DETERx applications and potential new indications, capitalizing on biopharma trends like precision medicine and abuse-resistant therapies.[1][3] Evolving regulations, pipeline advancements, and CSR integration will likely amplify its influence, potentially positioning it as a model for patient-centric growth in a scrutinized sector. This trajectory reinforces its foundational mission, transforming serious condition management for stronger communities.[1][2]